October 6, 2004.
Antibody development company Protein Design Labs Inc. said Wednesday animal study data shows its age-related blindness treatment helped prevent the blood vessel formation that can cause blindness.
The company said its F200 antibody fragment suppressed hemorrhaging and leakage in rabbits that had been induced to have new blood vessels grow in their eyes. F200 is intended to treat wet age-related macular degeneration, one of the leading causes of blindness in the elderly. The condition occurs when new blood vessels form in the eye and leak, blocking the retina.
F200 binds to a molecule critical to the formation of new blood vessels, alpha5beta1 integrin, and causes the new cells to die, the company said.
End of article.
Any further reproduction or distribution of this article in a format other than a specialized format is an infringement of copyright.
Go to ...
Top of Page.
List of Categories.
Blind World Website
Designed and Maintained by:
All Rights Reserved.